Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens.

por A'Hern, R. P., Smith, I. E., Ebbs, S. R.
Publicado 1993

Childhood T-cell lymphoblastic lymphoma--does early resolution of mediastinal mass predict for final outcome? The United Kingdom Children's Cancer Study Group (UKCCSG).

por Shepherd, S. F., A'Hern, R. P., Pinkerton, C. R.
Publicado 1995

Does chemotherapy improve survival in advanced breast cancer? A statistical overview.

por A'Hern, R. P., Ebbs, S. R., Baum, M. B.
Publicado 1988

Analysis of survival following treatment of tumour-induced hypercalcaemia with intravenous pamidronate (APD).

por Ling, P. J., A'Hern, R. P., Hardy, J. R.
Publicado 1995

Breast cancer, prostaglandins and patient survival.

por Bennett, A., Stamford, I. F., Berstock, D. A., Dische, F., Singh, L., A'Hern, R. P.
Publicado 1989

Duct carcinoma in situ: predictors of local recurrence and progression in patients treated by surgery alone.

por Price, P., Sinnett, H. D., Gusterson, B., Walsh, G., A'Hern, R. P., McKinna, J. A.
Publicado 1990

Platinum-Taxol non-cross resistance in epithelial ovarian cancer.

por Gore, M. E., Preston, N., A'Hern, R. P., Hill, C., Mitchell, P., Chang, J., Nicolson, M.
Publicado 1995

Immunohistochemical assay for epidermal growth factor receptor on paraffin-embedded sections: validation against ligand-binding assay and clinical relevance in breast cancer.

por Newby, J. C., A'Hern, R. P., Leek, R. D., Smith, I. E., Harris, A. L., Dowsett, M.
Publicado 1995

A prognostic index that predicts outcome following palliative whole brain radiotherapy for patients with metastatic malignant melanoma

por Morris, S L, Low, S H, A'Hern, R P, Eisen, T G, Gore, M E, Nutting, C M, Harrington, K J
Publicado 2004

Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients w...

por Johnston, S. R., Constenla, D. O., Moore, J., Atkinson, H., A'Hern, R. P., Dadian, G., Riches, P. G., Gore, M. E.
Publicado 1998

Head and neck sarcomas: prognostic factors and implications for treatment.

por Eeles, R. A., Fisher, C., A'Hern, R. P., Robinson, M., Rhys-Evans, P., Henk, J. M., Archer, D., Harmer, C. L.
Publicado 1993

Proliferation in human bladder carcinoma measured by Ki-67 antibody labelling: its potential clinical importance.

por Bush, C., Price, P., Norton, J., Parkins, C. S., Bailey, M. J., Boyd, J., Jones, C. R., A'Hern, R. P., Horwich, A.
Publicado 1991

Gefitinib (ZD1839, Iressa™) as palliative treatment in recurrent or metastatic head and neck cancer

por Kirby, A M, A'hern, R P, D'ambrosio, C, Tanay, M, Syrigos, K N, Rogers, S J, Box, C, Eccles, S A, Nutting, C M, Harrington, K J
Publicado 2006

Chemotherapy for ovarian cancer--a consensus statement on standard practice.

por Adams, M., A'Hern, R. P., Calvert, A. H., Carmichael, J., Clark, P. I., Coleman, R. E., Earl, H. M., Gallagher, C. J., Ganesan, T. S., Gore, M. E., Graham, J. D., Harper, P. G., Jayson, G. C., Kaye, S. B., Ledermann, J. A., Osborne, R. J., Perren, T. J., Poole, C. J., Radford, J. A., Rustin, G. J., Slevin, M. L., Smyth, J. F., Thomas, H., Wilkinson, P. M.
Publicado 1998